With biosimilars in the limelight, Kiran Mazumdar-Shaw’s company is poised to become one of India’s most important drug makers
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
Ahead of its IPO, the mobile telephony leader is down to playing catch-up with Airtel. What should investors expect?
Startups of all hues are lining up to hit the IPO market like never before, even as the economy sends distress signals. Can the equity market absorb this type of supply?
From the Byju’s flameout to the fresh Adani tempest, The Morning Context helped cut through the clutter around the big developments in Indian business.